ASCENDNCT07935135
Study of CMP-002 in Participants With SYNGAP1-Related Disorder
StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Safety and tolerability of multiple doses of CMP-002: incidence of adverse events and changes from baseline in clinical laboratory results
Timeframe: Screening to Week 36
Secondary (5)
CSF concentrations of the active drug substance of CMP-002 after multiple doses
Plasma PK of the active drug substance of CMP-002 after multiple doses: Cmax
Plasma PK of the active drug substance of CMP-002 after multiple doses: AUC(0-24h)
Urine PK of the active drug substance of CMP-002: Cmax
Urine PK of the active drug substance of CMP-002: AUC(0-24hr)
Arms and interventions
CMP-002 Multiple Ascending Dose (MAD)Experimental
Participants will be administered CMP-002 on Days 1, 29, and 85, and will be followed for 24 weeks after the last dose. Three dose levels will be evaluated.
Sham-prickSham comparator
Participants will receive the sham-prick procedure on Days 1, 29, and 85, and will be followed for 24 weeks after the last procedure.
Drugs: CMP-002
Other: Sham-prick
Sites
1 site in 1 country
- Hospital AlemánBuenos Aires, Argentina